Dominique Hussey comments in Bloomberg BNA on draft changes to Canada's patent litigation process for prescription drugs. She points out that the changes create new opportunities and challenges, introduce complexity into the litigation and will raise new procedural and substantive issues that have no precedent. The amendments could take effect as early as September 21, 2017, when the Comprehensive Economic Trade Agreement (CETA) that inspired the changes will be provisionally applied.
In The News
Dominique Hussey in Bloomberg on Canada's Pharmaceutical IP Rules
July 26, 2017
Republication Requests
To obtain permission to republish this publication or any other publication, contact Erica Wirthlin at wirthline@bennettjones.com.
For Informational Purposes Only
This publication provides an overview of trends and legal updates for informational purposes only. For personalized legal advice, please contact the authors.
From the Same Authors
See AllArticle
WTR: Trademark Litigation Review 2024
December 12, 2023Dominique T. Hussey & Melissa M. Dimilta
Article
Winning Strategies for Litigating Before Canadian Courts
November 24, 2023Dominique T. Hussey & Melissa M. Dimilta
Latest Insights
See All Insights See AllBlog
OPC Issues New PIPEDA Guidance on Assessing Third-Party Service Providers
September 14, 2026 & 2 more
Blog
Government of Canada Reduces the Scope of the Project List under the Impact Assessment Act
September 11, 2026Ashley M. White, Martin Ignasiak KC & Nathan Murray
Blog
BC Signs DRIPA Agreement Requiring Simpcw Consent for Yellowhead Copper Project
September 10, 2026 & 1 more

















